{"id":"metformin-and-saxagliptin","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Upper respiratory tract infection"},{"rate":"<0.1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":null,"_dailymed":{"setId":"fbd25da4-ebe6-45c9-beb8-93523d11a0b4","title":"KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [ASTRAZENECA PHARMACEUTICALS LP]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination of two oral antidiabetic agents with complementary mechanisms. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), thereby stimulating glucose-dependent insulin secretion and suppressing glucagon secretion.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while saxagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:24.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT07033585","phase":"PHASE2, PHASE3","title":"Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-06-15","conditions":"Type 2 Diabetes","enrollment":600},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT01267448","phase":"PHASE4","title":"Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2014-09-09","conditions":"Diabetes Mellitus Type 2, Hyperglycemia","enrollment":100},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT03714594","phase":"PHASE2","title":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02597101","phase":"PHASE2","title":"Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes","status":"COMPLETED","sponsor":"Nick Giannoukakis, PhD","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Insulin Resistance","enrollment":14},{"nctId":"NCT02407899","phase":"PHASE4","title":"Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes","status":"COMPLETED","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 1","enrollment":300},{"nctId":"NCT04796428","phase":"PHASE4","title":"GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial","status":"UNKNOWN","sponsor":"Center for Outcomes Research and Clinical Epidemiology, Italy","startDate":"2021-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":1167},{"nctId":"NCT04521049","phase":"PHASE4","title":"Tubular Markers in Response to Saxagliptin Therapy","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT04141163","phase":"PHASE1, PHASE2","title":"Metformin in Patients With Fragile X","status":"UNKNOWN","sponsor":"Rowan University","startDate":"2019-10-29","conditions":"Fragile X Syndrome","enrollment":40},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02551874","phase":"PHASE3","title":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":650},{"nctId":"NCT02681094","phase":"PHASE3","title":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-02-26","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":905},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT02280486","phase":"PHASE4","title":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":388},{"nctId":"NCT02304081","phase":"PHASE4","title":"Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function","status":"COMPLETED","sponsor":"Prof. Dr. Thomas Forst","startDate":"2015-01","conditions":"Type2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT02588859","phase":"","title":"Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-30","conditions":"Type 2 Diabetes","enrollment":1200},{"nctId":"NCT03138356","phase":"PHASE1","title":"Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":126},{"nctId":"NCT02104804","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Type 2 Diabetes Mellitus","enrollment":953},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT01754142","phase":"","title":"Korean Post-marketing Surveillance for Kombiglyze XR®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11-24","conditions":"Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT02022007","phase":"PHASE3","title":"Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis","status":"COMPLETED","sponsor":"Woman's","startDate":"2014-03","conditions":"Polycystic Ovary Syndrome, Disorder of Glucose Regulation","enrollment":38},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT02243176","phase":"PHASE4","title":"24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":689},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02946632","phase":"PHASE3","title":"Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2016-12","conditions":"Diabetes Mellitus, Type II","enrollment":104},{"nctId":"NCT02920801","phase":"PHASE4","title":"Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":31},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02368704","phase":"","title":"Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11","conditions":"Diabetes Mellitus, Type 2, Endoplasmic Reticulum Stress","enrollment":40},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT02605772","phase":"PHASE4","title":"Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT02138097","phase":"","title":"Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":615067},{"nctId":"NCT02462369","phase":"PHASE4","title":"Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"The Second Hospital of Nanjing Medical University","startDate":"2015-06","conditions":"Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR","enrollment":88},{"nctId":"NCT01525225","phase":"PHASE1","title":"Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":4},{"nctId":"NCT00683657","phase":"PHASE3","title":"Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":93},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00899470","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00757588","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes","enrollment":455},{"nctId":"NCT01192139","phase":"PHASE1","title":"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT00897390","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00918138","phase":"PHASE3","title":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT01068717","phase":"PHASE1","title":"Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-03","conditions":"Type 2 Diabetes Mellitus","enrollment":27},{"nctId":"NCT01192152","phase":"PHASE1","title":"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT01365091","phase":"PHASE1","title":"Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT01068743","phase":"PHASE1","title":"Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00374907","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes","enrollment":156},{"nctId":"NCT00313313","phase":"PHASE3","title":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Diabetes","enrollment":768},{"nctId":"NCT00316082","phase":"PHASE3","title":"Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Diabetes","enrollment":365},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306},{"nctId":"NCT00121667","phase":"PHASE3","title":"Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1462},{"nctId":"NCT01874080","phase":"PHASE1","title":"Bioequivalence Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Diabetes","enrollment":56},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT00121641","phase":"PHASE3","title":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1035},{"nctId":"NCT01960205","phase":"PHASE4","title":"Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2013-08","conditions":"Prediabetes","enrollment":80},{"nctId":"NCT01767389","phase":"","title":"Glucagon-like Peptide (GLP) Utilization and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT01305551","phase":"PHASE1","title":"BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01755494","phase":"PHASE1","title":"A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus(T2DM)","enrollment":64},{"nctId":"NCT01006603","phase":"PHASE4","title":"Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":957},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01128153","phase":"PHASE3","title":"Saxagliptin Triple Oral Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":257},{"nctId":"NCT00575588","phase":"PHASE3","title":"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-12","conditions":"Type 2 Diabetes","enrollment":891},{"nctId":"NCT00661362","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":570},{"nctId":"NCT01441869","phase":"PHASE1","title":"Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-10","conditions":"Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin","enrollment":28},{"nctId":"NCT01006590","phase":"PHASE4","title":"Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":286},{"nctId":"NCT00960076","phase":"PHASE3","title":"An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":282},{"nctId":"NCT01206647","phase":"PHASE4","title":"Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT00666458","phase":"PHASE3","title":"18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":822}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":309,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Metformin and Saxagliptin","genericName":"Metformin and Saxagliptin","companyName":"ikfe-CRO GmbH","companyId":"ikfe-cro-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while saxagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}